USD
+$0.00
(+0.00%
)At Close (As of Sep 5, 2025)
$113.41B
Market Cap
15.5
P/E Ratio
3
EPS
$57.57
52 Week High
$43.86
52 Week Low
HEALTHCARE
Sector
Field | Value (EUR) |
---|---|
Gross Profit | $31B |
Total Revenue | $44B |
Cost Of Revenue | $13B |
Costof Goods And Services Sold | $13B |
Operating Income | $7.3B |
Selling General And Administrative | $9.2B |
Research And Development | $7.4B |
Operating Expenses | $24B |
Investment Income Net | - |
Net Interest Income | -$560M |
Interest Income | $413M |
Interest Expense | $749M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3.6B |
Income Before Tax | $6.7B |
Income Tax Expense | $1.2B |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $5.6B |
Comprehensive Income Net Of Tax | - |
Ebit | $7.4B |
Ebitda | $11B |
Net Income | $5.6B |
Field | Value (EUR) |
---|---|
Total Assets | $133B |
Total Current Assets | $43B |
Cash And Cash Equivalents At Carrying Value | $7.4B |
Cash And Short Term Investments | $7.4B |
Inventory | $9.4B |
Current Net Receivables | $11B |
Total Non Current Assets | $90B |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $23B |
Intangible Assets Excluding Goodwill | $23B |
Goodwill | $43B |
Investments | - |
Long Term Investments | $3.3B |
Short Term Investments | $486M |
Other Current Assets | $15B |
Other Non Current Assets | - |
Total Liabilities | $55B |
Total Current Liabilities | $29B |
Current Accounts Payable | $7.6B |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $4.5B |
Total Non Current Liabilities | $26B |
Capital Lease Obligations | $1.9B |
Long Term Debt | $12B |
Current Long Term Debt | $4.2B |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $18B |
Other Current Liabilities | $16B |
Other Non Current Liabilities | $2.9B |
Total Shareholder Equity | $78B |
Treasury Stock | - |
Retained Earnings | - |
Common Stock | $2.5B |
Common Stock Shares Outstanding | $2.5B |
Field | Value (EUR) |
---|---|
Operating Cashflow | $9.1B |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $3.6B |
Capital Expenditures | $3.2B |
Change In Receivables | - |
Change In Inventory | -$477M |
Profit Loss | - |
Cashflow From Investment | -$4.4B |
Cashflow From Financing | -$5.8B |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | $4.7B |
Dividend Payout Common Stock | $4.7B |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$302M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $5.5B |
Field | Value (EUR) |
---|---|
Gross Profit | $31B |
Total Revenue | $44B |
Cost Of Revenue | $13B |
Costof Goods And Services Sold | $13B |
Operating Income | $7.3B |
Selling General And Administrative | $9.2B |
Research And Development | $7.4B |
Operating Expenses | $24B |
Investment Income Net | - |
Net Interest Income | -$560M |
Interest Income | $413M |
Interest Expense | $749M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3.6B |
Income Before Tax | $6.7B |
Income Tax Expense | $1.2B |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $5.6B |
Comprehensive Income Net Of Tax | - |
Ebit | $7.4B |
Ebitda | $11B |
Net Income | $5.6B |
Field | Value |
---|---|
Ex Dividend Date | 2025-05-09 |
Declaration Date | 2025-04-15 |
Record Date | 2025-05-09 |
Payment Date | 2025-06-12 |
Amount | 2.212154 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.